RIPK1-IN-38

RIPK1-IN-38 is an orally active RIPK1 inhibitor with an IC50 value of 27 nM. RIPK1-IN-38 can inhibit the phosphorylation of RIPK1 and its downstream signaling molecules RIPK3 and MLKL. RIPK1-IN-38 exhibits anti-necroptotic activity. RIPK1-IN-38 has excellent anti-inflammatory efficacy in both the SIRS model and GVHD model. RIPK1-IN-38 can be used for the research of inflammatory and immune-related diseases[1].

Product Specifications

CAS Number

[3092834-30-2]

UNSPSC

12352005

Target

Interleukin Related; Lactate Dehydrogenase; Mixed Lineage Kinase; Necroptosis; RIP kinase

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease

Field of Research

Inflammation/Immunology

Smiles

O=C(N[C@@H](C)C1=CC=C(F)C=C1)C2=C3N(C=CC(C4=CC5=C(N=C(NC(C6CC6)=O)S5)C=C4)=C3)N=C2

Molecular Formula

C27H22FN5O2S

Molecular Weight

499.56

References & Citations

[1]Zhang C, et al. Discovery of benzothiazole derivatives as novel orally receptor-interacting protein kinase 1 (RIPK1) inhibitors for inflammatory disease therapy. Eur J Med Chem. 2026;302 (Pt 3) :118380.